Roche

A therapy jointly developed by Switzerland’s Roche Holding AG and Cambridge, Mass.-based Blueprint Medicines Corp. was approved by the U.S. health regulator for the treatment of patients with a type of non-small cell lung cancer (NSCLC).

Eli Lilly is moving quickly to get the newly approved precision oncology treatment Retevmo for certain lung and thyroid cancers into the hands of patients.